Introduction
Since 1989, when Dubois et al. fi rst reported their experience with laparoscopic cholecystectomy [1] , abdominal surgery has increasingly moved toward a minimally invasive approach based on known benefi ts such as reduced pain, length of hospital stay, and complications. Laparoscopic procedures are now used for staging and therapy; therefore, the number of indications has steadily grown, due in part to the increased experience and skill of surgeons using these techniques, in parallel with improvements in visualization and instrumentation. Endoscopic, laparoscopic, and newly developed techniques such as natural orifi ce transluminal endoscopic surgery (NOTES) have provided additional tools and approaches for surgeons to improve patients' quality of life during the postoperative period, demonstrating decreased postsurgical pain, shorter hospital stay, and earlier return to work, together with a reduction in late abdominal wall complications, particularly ventral hernia, which occurs in 10%-15% of patients who undergo traditional open procedures [2] . Remaining controversy persists regarding the laparoscopic approach for various oncologic procedures, although support and evidence for the minimally invasive approach is growing [3, 4] .
Laparoscopic approaches for gastric cancer, in particular, have been more slowly accepted in the West, largely due to the lower incidence of gastric cancer in these countries. Therefore, although the role of laparoscopic gastric surgery in the West has developed with general acceptance for the treatment of benign conditions such as gastroesophageal refl ux and morbid obesity [5, 6] , the role of laparoscopic surgery for the treatment of malignant gastric disease remains less clear.
In 1992, Ohgami et al. reported the fi rst laparoscopic wedge resection (LWR) for the treatment of early gastric cancer (EGC) [7] . Ohashi et al. later developed the fi rst intragastric mucosal resection (IGMR) for
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Key words Minimally invasive surgery · Laparoscopy · Gastric cancer · Gastric adenocarcinoma · Gastric cancer in the West · Laparoscopic gastrectomy EGC of the stomach at the posterior wall [8] . The aim of both procedures was to restrict the extent of gastric resection in the treatment of malignant disease with low risk of lymph node metastasis, therefore reducing the physiologic side effects of a standard gastrectomy.
Studies in EGC, defi ned by the Japanese Gastric Association classifi cation system as a tumor with invasion restricted to the mucosa or submucosa regardless of the presence of lymph node metastases, have determined the risk of lymph node metastasis based on early gastric tumor characteristics [9] . Therefore, depth of invasion, grade of differentiation, and presence of ulcer [10] in EGC may determine the presence of local or distant nodal disease.
The Eastern experience in laparoscopic surgery for gastric cancer was limited to the two procedures noted above until 1994, when Kitano et al. performed the fi rst laparoscopy-assisted distal gastrectomy (LADG) with a modifi ed D1 lymph node dissection (D1 + left gastric artery group and D1 + common hepatic artery group) for the treatment of EGC with a high risk of lymph node metastasis [11] . This demonstrated the utility of laparoscopic surgery for gastric malignant disease in the East with regard to feasibility of an oncologically appropriate laparoscopic lymphadenectomy.
The development of laparoscopic surgery for malignant gastric disease in the West has been slower. This is partly related to skepticism regarding oncologic efficacy for this advanced surgical procedure, which has a signifi cant learning curve.
The Western experience with laparoscopic surgery for malignant gastric tumors had, until recently, been primarily confi ned to diagnostic laparoscopy as an adjunct to preoperative staging and stratifi cation of patients for neoadjuvant treatment of locally advanced tumors [12] , and more recently, for gastric LWR for gastrointestinal stromal tumors [13] , carcinoid tumors [14] , and early-stage adenocarcinoma [15, 16] . Laparoscopic distal, subtotal, and total gastrectomy for early and advanced gastric cancer is now emerging in the West with progressive acceptance among various groups, although this progress has been slowed by the difference in natural history of gastric adenocarcinoma in the East compared with the West.
Our interest is to review the current experience of laparoscopic gastric surgery in the West and the potential for progress as we advance our experience in the fi eld of minimally invasive gastric resection for cancer.
Natural history of gastric adenocarcinoma in the United States and other parts of the West
Gastric adenocarcinoma is the fourth-leading cause of cancer death in the United States, presenting in roughly 22 000 patients per year with more than 14 000 deaths [17] . Despite these alarming statistics, little progress has been made for this disease, perhaps due to the late stage of presentation and lack of surveillance screening programs in the West.
Although the Japanese have reported on an excellent experience where 70% of all gastric cancers are diagnosed at an early stage with an overall 5-year survival of more than 90% [18, 19] , there are epidemiologic differences between the East and West that may explain the different philosophy and approach towards gastric cancer treated in the United States and Europe [19] .
In the West, the frequency of gastric adenocarcinoma in the proximal third of the stomach is increasing, compared with the East, where adenocarcinoma of the middle and distal third still prevails [19] . Therefore, the increasing incidence of adenocarcinomas arising within the vicinity of the gastroesophageal junction (GEJ) with presentation at more advanced stages makes appropriate treatment recommendations challenging, and weighted toward neoadjuvant strategies, rather than minimally invasive procedures focused on early stages of the disease.
There has been much speculation regarding differences in outcome for gastric cancer patients in the Eastern versus Western world, especially considering the greater frequency of EGC in Japan (78 cases per 100 000 compared with the United States with 10 cases per 100 000) [20] . Hypotheses have included more accurate pathologic staging, extended nodal dissection, and meticulous histopathologic evaluation of surgical specimens [21] .
Schlemper et al. looked at pathologic interpretation of specimens and compared results between Japanese and Western pathologists [22] . They hypothesized that Japanese pathologists may classify a lesion as a carcinoma that Western pathologists classify as precursor lesions such as dysplasia or adenoma. The assessments of eight pathologists from North America, Europe, and Japan were compared after all individually reviewed microscopic slides of gastric lesions ranging from EGC to adenoma. The 17 biopsy samples reviewed were obtained from lesions in patients who underwent EMR, selecting only those with intestinal-type adenocarcinoma, since diffuse-type lesions do not give rise to confl icting diagnoses.
In this study, the distribution of diagnoses by all Western pathologists together was different from that by Japanese pathologists; 38% of the total diagnoses made by the Western group were defi nite carcinoma compared with 87% of the Japanese pathologists' diagnoses. Fifty-six percent of Western pathologists described adenoma and/or dysplasia, compared with 7% of the Japanese pathologists.
Schlemper et al. found that in Japan gastric cancer is diagnosed based on nuclear and structural criteria, not necessarily including invasion, thus potentially "upstaging" early lesions. The high proportion of early gastric carcinoma in Japan may be a refl ection of differences in the diagnostic criteria of intestinal-type EGC.
Another important issue concerning the natural history of GC in the West is the discrepancy in extent of lymphadenectomy. Limited DO/D1 surgery continues to be the most common surgical practice at some surgical centers in the West. There is controversy among Western surgeons about whether D2 dissection improves oncologic factors or simply improves tumor staging.
In the United States, multicenter randomized controlled trials (RCTs) have shown local (29%) and regional (72%) recurrence related to limited D0/D1 node dissection [23] , while multiple but nonrandomized prospective or retrospective studies in Japan and European specialized institutions suggest a survival advantage of D2 over D1 node dissection [24] [25] [26] . However, current Western philosophy recommends a minimum lymph node dissection of 15 nodes to ensure adequate staging information. In the past, the International Union against Cancer (UICC)/American Joint Committee on Cancer (AJCC) classifi cation system defi ned N stage by the location of lymph node metastases relative to the primary. Metastatic lymph nodes within 3 cm of the primary were considered N1; lymph node metastases more than 3 cm from the primary were N2. Though, in 1997 the UICC and AJCC redefi ned the pathologic nodal status based on the number of involved nodes and not by their location, recommending a minimum of 15 lymph nodes to be examined to defi ne N0 [27, 28] . Karpeh et al. demonstrated this via the analysis of 1038 patients with GC, showing that the location of positive nodes did not signifi cantly affect median survival compared with the number of positive nodes resected [29] . Therefore the N categories based on number rather than location would serve as better discriminators of median survival when 15 or more nodes are examined.
Despite these issues, the role of minimally invasive surgery for gastric cancer is expanding, although laparoscopic gastrectomy for cancer has emerged more conservatively than other applications of laparoscopy as a standard technique.
Laparoscopic surgery for early and late gastric cancer in the West
In 1999, Azagra et al. reported the fi rst laparoscopic total gastrectomy for cancer [30] . He and his group from Belgium have been Western pioneers in minimally invasive gastric resection for cancer, performing the fi rst totally laparoscopic distal gastrectomy with Billroth II anastomosis for cancer in 1993 [30] and the fi rst reported laparoscopic total gastrectomy for cancer a few years later [30] . Despite the relatively new advent of these techniques, there has been an aggressive approach to reporting series of patients undergoing laparoscopic resections for gastric cancers (Table 1) .
Huscher et al., from Italy, reported in the only Western prospective randomized trial to date so far, on 5-year clinical outcomes of laparoscopic-assisted subtotal gastrectomy compared with open subtotal gastrectomy for stage-matched adenocarcinomas, and demonstrated both safety and feasibility of the laparoscopic approach [31] . In this study, patients with a preoperative diagnosis of distal gastric cancer were prospectively randomized to undergo an open or a laparoscopic surgical procedure. Patients of both groups were matched by pTNM stage showing no signifi cant difference between groups; thus, 5-year survival numbers showed no signifi cant difference between the two groups, but provided patients of the laparoscopic group with the established benefi ts of minimally invasive surgery.
The experience in laparoscopic gastrectomy for the treatment of gastric adenocarcinoma in the West has therefore been mostly encouraged in Europe, with a small early experience in North America and South America published in recent years [32] [33] [34] [35] , with the largest United States series consisting of 15 patients who underwent minimally invasive gastrectomy or esophagogastrectomy for gastric cancer [33] .
In the United States, the fi rst group to describe their experience with laparoscopic gastrectomy with curative intent for GC was Reyes et al. from Mount Sinai Medical Center, in 2001 [32] . In this retrospective case-matched study with 36 patients (25 with malignant disease), they compared 18 laparoscopic surgeries with 18 open gastrectomies. Of those with GC, from the laparoscopic group, 9 patients had histologically confi rmed adenocarcinoma and 3 with carcinoid tumors compared with 12 adenocarcinomas and 1 gastric lymphoma in the open group. All resected margins in the laparoscopic group were free of tumor, whereas 2 patients in the open group (stages II and III) had R1 resections, likely related to selection bias for these more advanced, open cases [32] . There were no signifi cant differences in extent of lymph node dissection or in intraoperative complications between the two groups. The laparoscopic approach required a signifi cantly longer operative time (4.2 h vs 3.0 in the open group) likely related to the learning curve of this procedure. However, there was signifi cantly lower blood loss with fewer transfusions required, earlier return to normal bowel function, lower postoperative ileus, and signifi cantly reduced hospital stay in the laparoscopic versus open groups (6.3 vs 8.6 days).
In 2006, Varela et al. published the second experience with laparoscopic gastrectomy for GC in the United States, representing to date the largest American experience reported. After 15 consecutive laparoscopic gastrectomies, of which 2 were total, 4 proximal, 4 subtotal, 2 distal, and 3 laparoscopic esophagogastrectomies, no conversion to open surgery was reported, and there were no signifi cant differences in operative time, transfusion rate, number of lymph nodes resected, median length of stay, and morbidity, although there was signifi cantly lower blood loss among the laparoscopic group [33] , demonstrating both the feasibility and safety of the laparoscopic approach.
Conclusion
Open gastrectomy with a minimal lymph node dissection of 15 for staging purposes remains an appropriate surgical treatment for gastric adenocarcinoma in the West. With increasing experience and expertise of oncologic surgeons in the minimally invasive approach to gastric resection for cancer, it is becoming evident that laparoscopy, as a technique for resection, provides equivalent oncologic resections with lymphadenectomy that is comparable to the open approach, with no compromise in recurrence or long-term survival, based on preliminary studies. In addition, based on the known benefi ts of the minimally invasive approach, including reduced surgical trauma, blood loss, and pain, and quicker recovery for the patient, we are encouraged to expand our indications for this approach. This has been prompted also by advances in minimally invasive surgery for benign abdominal disease, and the results from multiple Eastern studies of early-stage cancer. Although an open approach should be applied for any case with concern over local resectability, defi nition of anatomy, or surgeon comfort level, it appears that the minimally invasive approach is here to stay. However, until more mature long-term follow-up data on advanced gastric cancer treated by minimally invasive approaches are defi ned in the West, where local clearance has been an issue in the open setting, we recommend that in centers that do not treat a large volume of gastric cancer, minimally invasive approaches should be limited to those patients with well-staged T1 and T2aN0 adenocarcinomas, as defi ned by computed tomography (CT) scan and endoscopic ultrasound. As the indications continue to expand for more advanced tumors and with the data from additional prospective studies, we will be able to more clearly defi ne the oncologically appropriate application of laparoscopic gastrectomy for all stages of gastric adenocarcinoma.
